Press coverage about Mylan N.V. (NASDAQ:MYL) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mylan N.V. earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave media stories about the company an impact score of 84 out of 100, indicating that recent press coverage is very likely to have an impact on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- $3.00 Billion in Sales Expected for Mylan N.V. (MYL) This Quarter (americanbankingnews.com)
- Financial Update of Mylan NV (NASDAQ:MYL) – appsforpcdaily.com – AppsforPCdaily (appsforpcdaily.com)
- Mylan Gets FDA’s Tentative Approval For “TLD” Under PEPFAR For HIV/AIDS (rttnews.com)
- Mylan NV (MYL) Shares Sold by Huntington National Bank (vothemes.com)
- Mylan down 4% premarket in sympathy with Teva; Q2 earnings August 9 (seekingalpha.com)
Several research firms have recently weighed in on MYL. Royal Bank Of Canada reduced their price objective on shares of Mylan N.V. from $39.00 to $36.00 and set a “sector perform” rating for the company in a research report on Thursday, May 11th. Wells Fargo & Company restated a “market perform” rating and set a $40.00 price objective on shares of Mylan N.V. in a research report on Wednesday, May 31st. Zacks Investment Research upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research report on Thursday, May 25th. BidaskClub upgraded shares of Mylan N.V. from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Barclays PLC upgraded shares of Mylan N.V. from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $47.00 to $50.00 in a report on Monday, May 22nd. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. Mylan N.V. has an average rating of “Buy” and a consensus target price of $50.21.
Shares of Mylan N.V. (NASDAQ MYL) traded down 0.66% during trading on Tuesday, hitting $31.79. The company had a trading volume of 11,391,234 shares. The stock has a 50-day moving average of $38.19 and a 200 day moving average of $39.19. The stock has a market capitalization of $17.04 billion, a price-to-earnings ratio of 31.76 and a beta of 1.27. Mylan N.V. has a 12-month low of $31.28 and a 12-month high of $50.40. Mylan N.V. also was the target of unusually large options trading on Monday. Stock investors acquired 9,410 call options on the company. This represents an increase of 250% compared to the average daily volume of 2,688 call options.
Mylan N.V. (NASDAQ:MYL) last issued its earnings results on Wednesday, May 10th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.01. The business had revenue of $2.72 billion during the quarter, compared to the consensus estimate of $2.81 billion. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The firm’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.76 earnings per share. On average, analysts predict that Mylan N.V. will post $5.12 EPS for the current fiscal year.
In other Mylan N.V. news, President Rajiv Malik sold 25,000 shares of Mylan N.V. stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the completion of the sale, the president now directly owns 799,855 shares in the company, valued at $31,994,200. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Anthony Mauro sold 10,000 shares of Mylan N.V. stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider now owns 140,653 shares of the company’s stock, valued at $5,626,120. The disclosure for this sale can be found here. Insiders own 0.69% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/mylan-n-v-myl-receives-daily-news-sentiment-rating-of-0-22-updated-updated-updated/1197078.html.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with our FREE daily email newsletter.